The risk or severity of adverse effects can be increased when Olanzapine is combined with Flunarizine. The therapeutic efficacy of Liraglutide can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Eltanolone. The risk or severity of adverse effects can be increased when Sumatriptan is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Etidocaine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Desloratadine. Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Olanzapine. The risk or severity of adverse effects can be increased when Linezolid is combined with Olanzapine. The metabolism of Olanzapine can be decreased when combined with Desipramine. Olanzapine may increase the QTc-prolonging activities of Leuprolide. Iproniazid may increase the serotonergic activities of Olanzapine. Olanzapine may increase the QTc-prolonging activities of Dronedarone. The serum concentration of Cefditoren can be decreased when it is combined with Olanzapine. The risk or severity of adverse effects can be increased when PF-477736 is combined with Olanzapine. The serum concentration of Olanzapine can be decreased when it is combined with Valproic Acid. Toloxatone may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Meclizine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Nalbuphine. The risk or severity of adverse effects can be increased when Vilazodone is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Vigabatrin. The risk or severity of adverse effects can be increased when Olanzapine is combined with Alphaprodine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Diphenoxylate. The risk or severity of adverse effects can be increased when Lormetazepam is combined with Olanzapine. The serum concentration of Olanzapine can be decreased when it is combined with Cyproterone acetate. The risk or severity of adverse effects can be increased when Olanzapine is combined with Atorvastatin. The risk or severity of adverse effects can be increased when Procarbazine is combined with Olanzapine. The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Olanzapine. The risk or severity of adverse effects can be increased when Mesoridazine is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Triprolidine. The risk or severity of adverse effects can be increased when Alprazolam is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ketazolam. The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Olanzapine. Caroxazone may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Dimenhydrinate. The metabolism of Olanzapine can be decreased when combined with Clotrimazole. The risk or severity of adverse effects can be increased when Promethazine is combined with Olanzapine. The metabolism of Olanzapine can be decreased when combined with Clemastine. Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Olanzapine may increase the QTc-prolonging activities of Dolasetron. The risk or severity of adverse effects can be increased when Olanzapine is combined with Procaine. The therapeutic efficacy of Alogliptin can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Gabapentin Enacarbil. Olanzapine may decrease the stimulatory activities of Hydroxyamphetamine. The metabolism of Olanzapine can be decreased when combined with Tranylcypromine. Olanzapine may increase the QTc-prolonging activities of Paliperidone. The therapeutic efficacy of Miglitol can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Canertinib. Olanzapine can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy. The risk or severity of adverse effects can be increased when Olanzapine is combined with clomethiazole. Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Tetracaine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Thiamylal. The risk or severity of adverse effects can be increased when Olanzapine is combined with Tasimelteon. The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Olanzapine. The serum concentration of Olanzapine can be increased when it is combined with Panobinostat. The risk or severity of adverse effects can be increased when Olanzapine is combined with Oxycodone. The risk or severity of adverse effects can be increased when Olanzapine is combined with Phenobarbital. The risk or severity of adverse effects can be increased when Olanzapine is combined with Oxethazaine. The metabolism of Olanzapine can be decreased when combined with Atomoxetine. Iproclozide may increase the serotonergic activities of Olanzapine. Olanzapine may increase the QTc-prolonging activities of Erythromycin. The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Olanzapine. Olanzapine may increase the sedative activities of Metyrosine. The risk or severity of adverse effects can be increased when Hydromorphone is combined with Olanzapine. Droperidol may increase the central nervous system depressant (CNS depressant) activities of Olanzapine. Olanzapine may increase the QTc-prolonging activities of Flecainide. The risk or severity of adverse effects can be increased when Olanzapine is combined with Benzocaine. Olanzapine may increase the antipsychotic activities of Amisulpride. The risk or severity of adverse effects can be increased when Olanzapine is combined with Barbital. The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Olanzapine. The metabolism of Olanzapine can be decreased when combined with Isoniazid. Olanzapine may decrease the stimulatory activities of Lisdexamfetamine. The metabolism of Olanzapine can be decreased when combined with Mexiletine. Desvenlafaxine may increase the serotonergic activities of Olanzapine. Olanzapine may increase the QTc-prolonging activities of Lumefantrine. Safrazine may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Etizolam is combined with Olanzapine. The risk or severity of adverse effects can be increased when Lorazepam is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Etomidate. The risk or severity of adverse effects can be increased when Olanzapine is combined with Zaleplon. Olanzapine may increase the QTc-prolonging activities of Clozapine. Minaprine may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Quazepam is combined with Olanzapine. The therapeutic efficacy of Gusperimus can be decreased when used in combination with Olanzapine. Olanzapine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine. The serum concentration of Nilotinib can be decreased when it is combined with Olanzapine. The risk or severity of adverse effects can be increased when Methylergometrine is combined with Olanzapine. The risk or severity of adverse effects can be increased when Nitrazepam is combined with Olanzapine. The risk or severity of adverse effects can be increased when Nicergoline is combined with Olanzapine. The therapeutic efficacy of Glibornuride can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Fentanyl. Olanzapine may increase the QTc-prolonging activities of Escitalopram. The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Eszopiclone. The risk or severity of adverse effects can be increased when Olanzapine is combined with Fospropofol. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ezogabine. Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. The serum concentration of Ledipasvir can be decreased when it is combined with Olanzapine. The risk or severity of adverse effects can be increased when Reserpine is combined with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Chloroquine. The risk or severity of adverse effects can be increased when Clonazepam is combined with Olanzapine. The risk or severity of adverse effects can be increased when Estazolam is combined with Olanzapine. Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. The metabolism of Olanzapine can be decreased when combined with Lobeglitazone. The metabolism of Olanzapine can be decreased when combined with Rucaparib. The risk or severity of adverse effects can be increased when Olanzapine is combined with Nitrous oxide. The therapeutic efficacy of Insulin Human can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Ergonovine is combined with Olanzapine. The metabolism of Olanzapine can be decreased when combined with Nevirapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Levobupivacaine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Dextropropoxyphene. The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Olanzapine. The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Gabapentin. The metabolism of Olanzapine can be decreased when combined with Paroxetine. The metabolism of Olanzapine can be decreased when combined with Tipranavir. Pivhydrazine may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Cyproheptadine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Glutethimide. The metabolism of Olanzapine can be decreased when combined with Bortezomib. Olanzapine may increase the QTc-prolonging activities of Domperidone. The risk or severity of adverse effects can be increased when Olanzapine is combined with Pomalidomide. The risk or severity of adverse effects can be increased when Olanzapine is combined with Amobarbital. The therapeutic efficacy of Buformin can be decreased when used in combination with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Bedaquiline. The serum concentration of Varenicline can be increased when it is combined with Olanzapine. Olanzapine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy. Etoperidone may increase the serotonergic activities of Olanzapine. Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. The risk or severity of adverse effects can be increased when Olanzapine is combined with Sepranolone.